hsCRP: Silent inflammation predicts heart risk over decades

High-sensitivity C-reactive protein (hsCRP) measures silent, low-grade inflammation in the blood. It gives you a separate piece of information about your cardiovascular risk that blood lipids alone don't show. In large long-term studies, higher hsCRP was linked to more heart attacks, strokes and cardiovascular deaths over 20 to 30 years, independent of cholesterol. That's why a second look is worthwhile, especially when your blood lipids seem unremarkable.

Key points at a glance

• hsCRP is a sensitive blood marker for low-grade, persistent inflammation in the body.
• In around 28,000 initially healthy US women, the top fifth of hsCRP levels was linked to a 70 percent higher 30-year risk of major cardiovascular events.
• A European study of more than 17,000 men and women confirmed this association over 20 years.
• In people whose cholesterol had already been lowered with medication, hsCRP predicted future events and deaths more strongly than LDL cholesterol.
• The studies show associations; a baseline plus regular re-testing shows where your level is heading.

What does hsCRP actually measure?

hsCRP measures how much C-reactive protein is circulating in the blood, using a test that also picks up very low amounts. This makes visible the silent background inflammation that causes no symptoms. Think of embers glowing under the ash: no fire you can see, but heat that keeps working for years.

This background inflammation matters for the blood vessels. A pooled analysis of 3 international trials with 31,245 patients in the Lancet (2023) states that inflammation and elevated blood lipids together contribute to the hardening and blockage of arteries. So hsCRP and blood lipids describe two different pathways of the same process.

One important practical point: CRP also rises sharply during an acute infection. What carries meaning is the stable baseline between two colds, rather than a brief spike.

How strongly is hsCRP linked to heart risk?

In several large long-term studies, hsCRP is clearly and independently linked to later cardiovascular risk. The findings are remarkably consistent across continents, sexes and decades.

A long-term study of 27,939 initially healthy US women in the New England Journal of Medicine (2025) followed participants for 30 years; their average age at the start was 54.7 years. Women in the top fifth of hsCRP levels had a 70 percent higher risk of a first major cardiovascular event (heart attack, stroke, coronary procedure or cardiovascular death) than women in the bottom fifth. That association was stronger than the one for LDL cholesterol in the same study.

The EPIC-Norfolk study of 17,087 initially healthy men and women in the European Heart Journal (2025) confirmed the pattern over 20 years. The top fifth of hsCRP levels was linked to a 55 percent higher risk of major cardiovascular events, and the results were the same for men and women.

An analysis of the UK Biobank with 215,695 adults aged 40 to 69 in the Journal of the American College of Cardiology (2026) found a 64 percent higher risk of coronary artery disease over 12 years with elevated hsCRP. All the markers studied had stronger predictive power in younger people.

Why does inflammation matter even when cholesterol is lowered?

Even when blood lipids are already being treated, inflammation remains a separate risk pathway. That is exactly what the Lancet analysis shows, covering 31,245 people who had vascular disease or a high risk of it and were already taking cholesterol-lowering medication.

In the top quarter of hsCRP levels, the risk of cardiovascular death was 2.68 times higher and the risk of death from any cause 2.42 times higher than in the bottom quarter. For remaining LDL cholesterol, by contrast, the association with major cardiovascular events was neutral. The authors conclude that in this group, inflammation was a stronger predictor than cholesterol.

What this means for you: well-managed blood lipids are an important building block. But they tell only part of the story, and hsCRP adds the other part.

Why is a single hsCRP reading only the beginning?

A single hsCRP reading is a snapshot; only the trend shows whether your background inflammation is stable, rising or falling. Even one measurement carried information over decades in the studies. Repeated measurements also separate the true baseline from a temporary spike.

There's another factor: risk rarely comes from a single pathway. In the EPIC-Norfolk study, risk rose with each additional elevated marker, to 1.33 times with one, 1.68 times with two and 2.41 times with three markers in the top fifth. Looking at several pathways together gives a much sharper picture than one value alone.

The limits of the evidence belong here too: these studies show associations. They don't answer whether risk falls if you deliberately lower your hsCRP. In the studies cited, hsCRP carried its own information about later cardiovascular risk, in addition to blood lipids, and in the UK Biobank study the marker was especially informative at younger ages.

When to see a doctor?

If your hsCRP is elevated repeatedly, you should discuss it with a doctor. This applies especially if cardiovascular disease runs in your family or if other values such as ApoB, blood pressure or blood sugar are unusual. A single outlier, for example during a cold, is a reason to re-test, not a diagnosis. If you have acute symptoms such as chest pain or shortness of breath, seek medical help immediately. The assessment and every treatment decision always rest with your doctor.

How Chirayou can help

The CHIRAYOU blood test measures hsCRP conveniently at home, with a capillary blood sample, no venous needle and no fasting. The same test covers other markers that fit the vascular and metabolic picture, including apolipoprotein B (ApoB, the count of cholesterol-carrying particles that build up in artery walls), triglycerides, fructosamine and gamma-GT. A doctor discusses your results with you.

In the 90-day program, this becomes a cycle of Test, Plan, Act. Together with our doctors, you build a plan with levers such as movement, nutrition, sleep, weight and alcohol. The next test then shows whether hsCRP and the other markers have actually moved. In the program, we look at hsCRP in the Reset category alongside visceral fat, which we score as a signal of metabolic inflammation.

Your next step: start with the CHIRAYOU blood test and establish your hsCRP baseline.

The bottom line

hsCRP makes visible a risk pathway that blood lipids alone don't show: silent inflammation. Large long-term studies link higher levels to more cardiovascular events over decades, even when cholesterol is unremarkable or already lowered. A baseline and regular re-testing show you where your background inflammation is heading.

This article is for general information only and does not replace medical advice, diagnosis or treatment.